Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538540 | 1.00 | POLB (0.59) | POLBMEN1KMT2AHRH3GBA1 | |
| SCHEMBL899608 | 1.00 | POLB (0.59) | POLBMEN1KMT2AHRH3GBA1 | |
| SCHEMBL15669880 | 0.98 | POLB (0.57) | POLBMEN1KMT2AHRH3GBA1 | |
| SCHEMBL1897843 | 0.98 | POLB (0.57) | POLBMEN1KMT2AHRH3GBA1 | |
| SCHEMBL23802807 | 0.98 | POLB (0.57) | POLBMEN1KMT2AHRH3GBA1 | |
| SCHEMBL23802919 | 0.98 | POLB (0.57) | POLBMEN1KMT2AHRH3GBA1 | |
| Bromide SCHEMBL15670016 | 0.95 | POLB (0.55) | POLBMEN1KMT2AHRH3 | |
| SCHEMBL10981485 | 0.86 | MEN1 (0.47) | POLBMEN1KMT2AHRH3 | |
| SCHEMBL28311651 | 0.85 | POLB (0.50) | POLBMEN1KMT2AGBA1 | |
| SCHEMBL16738 | 0.83 | POLB (0.58) | POLBMEN1KMT2AHRH3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569625-A1 | POLYURETHANE HOTMELT ADHESIVE WHICH DO NOT CAUSE POLARIZER DISCOLORATION AT HTHH CONDITON | Henkel AG & Co. KGaA (DE) | 2019-11-20 | — | — | EP | claimed |
| CN-107382997-A | For preparing the method and intermediate of drug agents | 吉利德科学公司 | 2017-11-24 | — | — | CN | claimed |
| CN-104876888-A | Methods And Intermediates For Preparing Pharmaceutical Agents | GILEAD SCIENCES INC | 2015-09-02 | — | — | CN | claimed |
| CN-104745007-A | GRAPHENE COMPOSITE AND METHOD FOR PREPARING THE SAME | DONGJIN SEMICHEM CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-102438982-B | process for the preparation of cytochrome P450 monooxygenase inhibitors and intermediates involved | GILEAD SCIENCES INC | 2015-05-06 | — | — | CN | claimed |
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2015-01-01 | — | — | US | claimed |
| US-8497396-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2013-07-30 | — | — | US | claimed |
| EP-2414325-A2 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED | Gilead Sciences, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2010-10-07 | — | — | US | claimed |
| WO-2010115000-A2 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-4042523-A | Olefin-thionophosphine sulfide reaction products, their derivatives and use thereof as oil and fuel additives | EXXON RESEARCH AND ENGINEERING CO. (US) | 1977-08-16 | — | — | US | disclosed |
| US-4018849-A | Polyurethane polyol compositions modified with an alkylenimine | PPG INDUSTRIES, INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3975348-A | Water-extended polyesteramide resins and methods for their production | VULCAN MATERIALS COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966667-A | Preparation of non-aqueous thermosetting acrylic polymer dispersions | PPG INDUSTRIES, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3953391-A | ALKYLENEIMINE-MODIFIED ACRYLIC COPOLYMERSACID | PPG INDUSTRIES, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | POLB 3555/4885MEN1 2092/4885KMT2A 1539/4885 |
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | POLB 790/4885MEN1 366/4885KMT2A 4442/4885 |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | POLB 790/4885MEN1 366/4885KMT2A 4442/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | POLB 3828/4885MEN1 1840/4885KMT2A 1784/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | POLB 3828/4885MEN1 1840/4885KMT2A 1784/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | POLB 3877/4885MEN1 1784/4885KMT2A 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.